PMID- 20357375
OWN - NLM
STAT- MEDLINE
DCOM- 20101021
LR  - 20220321
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 33
IP  - 7
DP  - 2010 Jul
TI  - The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating 
      endothelial progenitor cells in patients with type 2 diabetes: possible role of 
      stromal-derived factor-1alpha.
PG  - 1607-9
LID - 10.2337/dc10-0187 [doi]
AB  - OBJECTIVE: Vasculoprotective endothelial progenitor cells (EPCs) are regulated by 
      stromal-derived factor-1alpha (SDF-1alpha) and are reduced in type 2 diabetes. 
      Because SDF-1alpha is a substrate of dipeptidyl-peptidase-4 (DPP-4), we 
      investigated whether the DPP-4 inhibitor sitagliptin modulates EPC levels in type 
      2 diabetic patients. RESEARCH DESIGN AND METHODS: This was a controlled, 
      nonrandomized clinical trial comparing 4-week sitagliptin (n = 16) versus no 
      additional treatment (n = 16) in addition to metformin and/or secretagogues in 
      type 2 diabetic patients. We determined circulating EPC levels and plasma 
      concentrations of SDF-1alpha, monocyte chemoattractant protein-1 (MCP-1), 
      vascular endothelial growth factor (VEGF), and nitrites/nitrates. RESULTS: There 
      was no difference in clinical baseline data between the sitagliptin and control 
      arms. After 4 weeks, as compared with control subjects, patients receiving 
      sitagliptin showed a significant increase in EPCs and SDF-1alpha and a decrease 
      in MCP-1. CONCLUSIONS: Sitagliptin increases circulating EPCs in type 2 diabetic 
      patients with concomitant upregulation of SDF-1alpha. This ancillary effect of 
      DPP-4 inhibition might have potential favorable cardiovascular implications.
FAU - Fadini, Gian Paolo
AU  - Fadini GP
AD  - Department of Clinical and Experimental Medicine, School of Medicine, University 
      of Padova, Padova, Italy. gianpaolofadini@hotmail.com.
FAU - Boscaro, Elisa
AU  - Boscaro E
FAU - Albiero, Mattia
AU  - Albiero M
FAU - Menegazzo, Lisa
AU  - Menegazzo L
FAU - Frison, Vera
AU  - Frison V
FAU - de Kreutzenberg, Saula
AU  - de Kreutzenberg S
FAU - Agostini, Carlo
AU  - Agostini C
FAU - Tiengo, Antonio
AU  - Tiengo A
FAU - Avogaro, Angelo
AU  - Avogaro A
LA  - eng
SI  - ClinicalTrials.gov/NCT00968006
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20100331
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (CXCL12 protein, human)
RN  - 0 (CXCR4 protein, human)
RN  - 0 (Chemokine CXCL12)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Pyrazines)
RN  - 0 (Receptors, CXCR4)
RN  - 0 (Triazoles)
RN  - 9100L32L2N (Metformin)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Chemokine CXCL12/*metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism/pathology
MH  - Dipeptidyl Peptidase 4/metabolism
MH  - Dipeptidyl-Peptidase IV Inhibitors/*administration & dosage
MH  - Drug Therapy, Combination
MH  - Endothelial Cells/cytology
MH  - Enzyme Activation/drug effects
MH  - Female
MH  - Hematopoietic Stem Cells/cytology/*drug effects
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage
MH  - Male
MH  - Metformin/administration & dosage
MH  - Middle Aged
MH  - Pilot Projects
MH  - Pyrazines/*administration & dosage
MH  - Receptors, CXCR4/metabolism
MH  - Sitagliptin Phosphate
MH  - Triazoles/*administration & dosage
PMC - PMC2890368
EDAT- 2010/04/02 06:00
MHDA- 2010/10/22 06:00
PMCR- 2011/07/01
CRDT- 2010/04/02 06:00
PHST- 2010/04/02 06:00 [entrez]
PHST- 2010/04/02 06:00 [pubmed]
PHST- 2010/10/22 06:00 [medline]
PHST- 2011/07/01 00:00 [pmc-release]
AID - dc10-0187 [pii]
AID - 0187 [pii]
AID - 10.2337/dc10-0187 [doi]
PST - ppublish
SO  - Diabetes Care. 2010 Jul;33(7):1607-9. doi: 10.2337/dc10-0187. Epub 2010 Mar 31.